Yoshiki Ryoma
- Co-authors
- Yoichiro MoriyaMotoo SaitoMasato OkamotoMitsunobu SatoTetsuya OshikawaTomoyuki TanoSharif AhmedShin Kan
- Topics
- Immune Response and Inflammation (10 papers)Immunotherapy and Immune Responses (6 papers)Immune Cell Function and Interaction (3 papers)
- Cited by
- ImmunologyOncologyMicrobiology
- Partner nations
- JapanUnited States
In The Last Decade
Yoshiki Ryoma
15 papers receiving 440 citations
Peers
Comparison fields: 5 of 62
- Immunology 314
- Oncology 158
- Molecular Biology 90
- Pulmonary and Respiratory Medicine 58
- Surgery 42
Countries citing papers authored by Yoshiki Ryoma
This map shows the geographic impact of Yoshiki Ryoma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshiki Ryoma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshiki Ryoma more than expected).
Fields of papers citing papers by Yoshiki Ryoma
This network shows the impact of papers produced by Yoshiki Ryoma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshiki Ryoma. The network helps show where Yoshiki Ryoma may publish in the future.
Co-authorship network of co-authors of Yoshiki Ryoma
This figure shows the co-authorship network connecting the top 25 collaborators of Yoshiki Ryoma. A scholar is included among the top collaborators of Yoshiki Ryoma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshiki Ryoma. Yoshiki Ryoma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 11 | |
| 2 | 21 | |
| 3 | Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer. | 27 |
| 4 | 55 | |
| 5 | 5 | |
| 6 | 30 | |
| 7 | 7 | |
| 8 | 91 | |
| 9 | Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. | 48 |
| 10 | 12 | |
| 11 | 67 | |
| 12 | Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells. | 20 |
| 13 | 29 | |
| 14 | 13 | |
| 15 | 13 |
About Yoshiki Ryoma
Yoshiki Ryoma is a scholar working on Immunology, Microbiology and Gastroenterology, having authored 15 papers that have together received 449 indexed citations. Recurring topics across this work include Immune Response and Inflammation (10 papers), Immunotherapy and Immune Responses (6 papers) and Immune Cell Function and Interaction (3 papers). The work is most often cited by research in Immunology (314 citations), Oncology (158 citations) and Microbiology (25 citations). Yoshiki Ryoma has collaborated with scholars based in Japan and United States. Frequent co-authors include Yoichiro Moriya, Motoo Saito, Masato Okamoto, Mitsunobu Sato, Tetsuya Oshikawa, Tomoyuki Tano, Sharif Ahmed, Shin Kan, Sachiko Furuichi and Kensuke Miyake. Their work appears in journals such as JNCI Journal of the National Cancer Institute, PLANT PHYSIOLOGY and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.